Report cover image

Second Generation Antipsychotics Market, By Indication (Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Autism Spectrum Disorder, and Other Indications), By Drug Class (Risperidone, Quetiapine, Olanzapine, Aripiprazole, Asenapine, Clozapine, P

Published May 05, 2025
Length 140 Pages
SKU # CMI20081476

Description

The global second generation antipsychotics market has witnessed significant growth in recent years, driven by the increasing prevalence of mental health disorders and the rising demand for effective treatments. Second generation antipsychotics, also known as atypical antipsychotics, have emerged as a preferred choice for the management of various psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. These medications offer several advantages over first generation antipsychotics, such as improved efficacy, reduced extrapyramidal side effects, and better tolerability. The market for second generation antipsychotics is expected to continue its upward trajectory, fueled by the growing awareness about mental health, the development of novel formulations, and the expanding indications for these drugs.

Market Dynamic:

The global second generation antipsychotics market is driven by several factors, including the growing geriatric population, and the increasing awareness about mental health. The World Health Organization estimates that around 450 million people globally suffer from mental health disorders, creating a significant demand for effective treatments. Additionally, the development of long-acting injectable formulations of second generation antipsychotics has improved patient compliance and convenience, further driving market growth. However, the market also faces certain restraints, such as the high cost of these medications, the potential for side effects, and the stigma associated with mental health disorders. Patent expiration of key drugs and the emergence of generic alternatives may also impact the market dynamics. Nevertheless, the market presents substantial opportunities for growth, driven by the increasing focus on personalized medicine, the development of novel drug delivery systems, and the expanding applications of second generation antipsychotics in the treatment of other psychiatric disorders.

Key Features of the Study:
  • This report provides in-depth analysis of the global second generation antipsychotics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global second generation antipsychotics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Lundbeck, Sanofi, Merck & Co., AbbVie, Takeda Pharmaceutical, Amgen, GlaxoSmithKline, and Alkermes
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global second generation antipsychotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global second generation antipsychotics market
Market Segmentation
  • Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Schizophrenia
  • Bipolar Disorder
  • Major Depressive Disorder
  • Autism Spectrum Disorder
  • Other Indications
  • Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Asenapine
  • Clozapine
  • Paliperidone
  • Brexpiprazole
  • Lurasidone
  • Others
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Parenteral
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
  • Key Players Insights
  • Johnson & Johnson
  • Eli Lilly and Company
  • AstraZeneca
  • Bristol-Myers Squibb
  • Pfizer
  • Novartis
  • Otsuka Pharmaceutical
  • Lundbeck
  • Sanofi
  • Merck & Co.
  • AbbVie
  • Takeda Pharmaceutical
  • Amgen
  • GlaxoSmithKline
  • Alkermes

Table of Contents

140 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Global Second Generation Antipsychotics Market, By Indication
Global Second Generation Antipsychotics Market, By Drug Class
Global Second Generation Antipsychotics Market, By Route of Administration
Global Second Generation Antipsychotics Market, By Distribution Channel
Global Second Generation Antipsychotics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
Industry Trends
4. Global Second Generation Antipsychotics Market, By Indication, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Schizophrenia
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bipolar Disorder
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Major Depressive Disorder
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Autism Spectrum Disorder
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Indications
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Second Generation Antipsychotics Market, By Drug Class, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Risperidone
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Quetiapine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Olanzapine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Aripiprazole
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Asenapine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Clozapine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Paliperidone
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Brexpiprazole
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lurasidone
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Second Generation Antipsychotics Market, By Route of Administration, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Second Generation Antipsychotics Market, By Distribution Channel, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Second Generation Antipsychotics Market, By Region, 2020 - 2032, Value (USD Bn)
Introduction
Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
Regional Trends
North America
Introduction
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
South Africa
North Africa
Central Africa
9. Competitive Landscape
Johnson & Johnson
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bristol-Myers Squibb
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Otsuka Pharmaceutical
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Lundbeck
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AbbVie
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Takeda Pharmaceutical
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Amgen
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
GlaxoSmithKline
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Alkermes
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
10. Analyst Recommendations
Wheel of Fortune
Analyst View
Coherent Opportunity Map
11. References and Research Methodology
References
Research Methodology
About us
*Browse 32 market data tables and 28 figures on 'Second Generation Antipsychotics Market' - Global forecast to 2032
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.